Phase 0 I II Cancer Prevention Clinical Trials Program
Gastrointestinal and Other Cancers
National Cancer Institute (NCI)
Active, not recruiting
For more information, see ClinicalTrials.gov NCT02521285
This randomized phase II trial studies the safety of and how well aspirin works in preventing Barrett's esophagus from returning after it has been successfully eliminated by radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus for the levels of a specific protein that is linked to developing Barrett's esophagus may help doctors learn whether aspirin can prevent it from returning after it has been successfully treated.
Aspirin, Laboratory Biomarker Analysis, Questionnaire Administration, Placebo Administration
Robert S Bresalier